EANS-News: Agennix AG Announces Corporate Restructuring

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, August 24,
2012 (euro adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today
announced a restructuring that involves staff reductions of
approximately 55 percent of the Company's workforce. The
restructuring is being implemented to conserve cash as management
determines the next strategic steps for the Company.

Torsten Hombeck, Ph.D., Chief Financial Officer and Spokesperson of
the Management Board, said: "Our immediate objective of conserving
cash has sadly necessitated significant staff reductions in both
Germany and the U.S. I would like to express my sincere appreciation
to our affected employees for their valuable contributions to
Agennix. We are working with our Supervisory Board to determine the
Company's direction and will provide an update in the near future."

The Company's restructuring plan involves a total staff reduction of
37 employees, which will take place in two tranches. The Houston site
will be shut down as a result of the restructuring. Following the
completion of this restructuring in November of this year, the
Company will have a total of 30 employees, who are being retained to
work on certain ongoing activities related to the talactoferrin
program, as well as to assist in the assessment of the Company's
strategic options.

Cash guidance The Company indicated that it expects to have
sufficient cash to fund operations into the first quarter of 2013.
The one-time cost of this restructuring and expenses related to
terminating various activities and operations will in the near term
offset anticipated longer-term savings from these cuts. As of June
30, 2012, cash, cash equivalents, other current financial assets and
restricted cash totaled EUR 22.7 million.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially lengthen and improve the lives of
critically ill patients in areas of major unmet medical need. The
Company's most advanced investigational agent is talactoferrin alfa,
which is currently being studied for the treatment of non-small cell
lung cancer. Other clinical development programs include RGB-286638,
a multi-targeted kinase inhibitor in Phase I testing for cancer, and
a topical gel form of talactoferrin for diabetic foot ulcers.
Agennix's registered seat is in Heidelberg, Germany. The Company has
three sites of operation: Planegg/Munich, Germany; Princeton, New
Jersey and Houston, Texas. For additional information, please visit
the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG,
including statements about cash reach. Such statements are based on
current expectations and are subject to risks and uncertainties, many
of which are beyond our control, that could cause future results,
performance or achievements to differ significantly from those
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. The
achievement of positive results in early stage clinical studies does
not ensure that later stage clinical studies will be successful.
There can be no guarantee that the Company will have or be able to
obtain the financial resources to conduct additional studies with its
product candidates or that it will be successful in pursuing other
business opportunities. Forward-looking statements speak only as of
the date on which they are made and Agennix undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.

Agennix® is a trademark of Agennix AG.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
regulated dealing/prime standard: Frankfurt
language: English